Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040
- 1Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Abstract
Background: Pancreatic cancer is a highly lethal malignancy for which mortality remains close to incidence. We combined complementary global estimates and longitudinal cancer-registry data to characterize its current burden, recent incidence trends, and demographic implications to 2040.
Methods: GLOBOCAN 2020 was used for cross-sectional estimates of pancreatic cancer incidence and mortality in 185 countries and territories. Continuous annual incidence trends from 2000 to 2017 were estimated from selected non-overlapping CI5plus registry populations with complete coverage over the study period. Age-standardized rates were calculated using the Segi–Doll world standard population. Log-linear models and continuous segmented regression selected by the Bayesian information criterion were used to estimate annual percentage changes (APCs). IARC Cancer Tomorrow fixed-risk demographic projections were used to estimate incident cases through 2040; annual risk-change scenarios of −0.5% and +0.5% were examined as sensitivity analyses.
Results: In 2020, an estimated 495,773 pancreatic cancer cases and 466,003 deaths occurred worldwide; the ASIR and ASMR were 4.86 and 4.53 per 100,000, respectively, and the mortality-to-incidence ratio was 0.94. Northern America and Europe had the highest regional ASIRs (8.04 and 7.77), whereas Asia contributed the largest number of cases (233,701). In pooled selected CI5plus populations, incidence increased during 2000–2006 (APC 1.43%, 95% CI 1.27–1.59) and 2006–2017 (APC 1.02%, 95% CI 0.94–1.10). The relative increase was greatest among adults younger than 50 years (APC 1.61%, 95% CI 1.37–1.85), although their absolute rate remained low. Under the fixed-risk demographic scenario, global incident cases were projected to reach 843,772 in 2040, a 70.2% increase from 2020.
Conclusion: Pancreatic cancer imposes a substantial and geographically unequal burden, with mortality remaining close to incidence. Combining GLOBOCAN with CI5plus distinguishes contemporary global burden from observed registry-based trends and supports risk-based surveillance, registry strengthening, and health-system capacity planning.
Related
- Nationwide trends and demographic projections of hospitalisations for vertebral fractures and postmenopausal osteoporosis in Germany: a 24-year registry-based study.
- Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis
- Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions
- Bladder cancer in Africa, 2010-2023: burden, geographic heterogeneity, demographic drivers, pandemic-era temporal changes, and projections to 2030.
- Epidemiological transitions of Visceral Leishmaniasis in G20 countries: A 33-year retrospective joinpoint and demographic decomposition analysis with 20-year ARIMA projections
BibTeX
@article{jin2026global,
title = {{Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040}},
author = {Xin Jin and Xiao Guan and Yongrun Mu and Min Wang and Chengfeng Wang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1850604},
url = {https://doi.org/10.3389/fonc.2026.1850604},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040
AU - Xin Jin
AU - Xiao Guan
AU - Yongrun Mu
AU - Min Wang
AU - Chengfeng Wang
PY - 2026
DA - 2026/10/12
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1850604
UR - https://doi.org/10.3389/fonc.2026.1850604
AB - Background: Pancreatic cancer is a highly lethal malignancy for which mortality remains close to incidence. We combined complementary global estimates and longitudinal cancer-registry data to characterize its current burden, recent incidence trends, and demographic implications to 2040. Methods: GLOBOCAN 2020 was used for cross-sectional estimates of pancreatic cancer incidence and mortality in 185 countries and territories. Continuous annual incidence trends from 2000 to 2017 were estimated from selected non-overlapping CI5plus registry populations with complete coverage over the study period. Age-standardized rates were calculated using the Segi–Doll world standard population. Log-linear models and continuous segmented regression selected by the Bayesian information criterion were used to estimate annual percentage changes (APCs). IARC Cancer Tomorrow fixed-risk demographic projections were used to estimate incident cases through 2040; annual risk-change scenarios of −0.5% and +0.5% were examined as sensitivity analyses. Results: In 2020, an estimated 495,773 pancreatic cancer cases and 466,003 deaths occurred worldwide; the ASIR and ASMR were 4.86 and 4.53 per 100,000, respectively, and the mortality-to-incidence ratio was 0.94. Northern America and Europe had the highest regional ASIRs (8.04 and 7.77), whereas Asia contributed the largest number of cases (233,701). In pooled selected CI5plus populations, incidence increased during 2000–2006 (APC 1.43%, 95% CI 1.27–1.59) and 2006–2017 (APC 1.02%, 95% CI 0.94–1.10). The relative increase was greatest among adults younger than 50 years (APC 1.61%, 95% CI 1.37–1.85), although their absolute rate remained low. Under the fixed-risk demographic scenario, global incident cases were projected to reach 843,772 in 2040, a 70.2% increase from 2020. Conclusion: Pancreatic cancer imposes a substantial and geographically unequal burden, with mortality remaining close to incidence. Combining GLOBOCAN with CI5plus distinguishes contemporary global burden from observed registry-based trends and supports risk-based surveillance, registry strengthening, and health-system capacity planning.
SN - 2234-943X
ER -